Ikena Oncology Inc
Research Ikena Oncology Inc (IMA) on Bullrun: market cap USD 47.94M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 47.94M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 10.18M
- Free cash flow-USD 9.07M
Valuation Snapshot
latest market cap is USD 47.94M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 800.00K | -USD 45.35M | -USD 47.84M | n/a | -9.64 | USD 94.53M | USD 0 | USD 133.14M |
| FY2024 | USD 3.50M | -USD 36.57M | -USD 21.32M | n/a | -22.1 | USD 12.12M | USD 7.50M | -USD 160.57M |
| FY2023 | USD 9.16M | -USD 68.17M | -USD 80.16M | n/a | -1.63 | USD 119.89M | USD 983.00K | -USD 126.11M |
| FY2022 | USD 15.62M | -USD 68.77M | -USD 75.54M | n/a | -1.9 | USD 59.92M | n/a | USD 146.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 47.94M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 77.15M | n/a | n/a | n/a |
About Ikena Oncology Inc
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ikena Oncology Inc's market cap?
Ikena Oncology Inc's market capitalization is USD 47.94M.
What does Ikena Oncology Inc do?
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.